Contact Us

Oral Osteoporosis Drug Side Effects Esophageal Cancer Risk
*    Denotes required field.

   * First Name 

   * Last Name 

   * Email 

   * Phone 

Cell Phone 

Street Address 

Zip Code 

City 

State 

Date you started taking this drug:

Date you stopped taking this drug:

Were you diagnosed with Esophogeal Cancer?

Please describe side effects:

No Yes, I agree to the Parker Waichman LLP disclaimers. Click here to review.

Yes, I would like to receive the Parker Waichman LLP monthly newsletter, InjuryAlert.

please do not fill out the field below.

Bisphosphonates-Esophageal Cancer

oral ostepororsis, esophogeal cancer risk, side effects, lawsuits

AddThis Social Bookmark Button

Oral Osteoporosis, Bisphosphonates Drugs, Esophageal Cancer Side Effects Lawsuits

Oral Osteoporosis Drugs, Esophageal Cancer Risk, Throat, Oral Cancer, Side Effects, Lawsuits | Bisphosphonates, Fosamax, Actonel, Boniva, Atelvia, Didronel, Skelid, FDA Warning

Have you been diagnosed with esophageal cancer while taking oral bisphosphonates such as, - Fosamax, Actonel, Boniva, Atelvia, Didronel, or Skelid - for osteoporosis? The U.S. Food & Drug Administration (FDA) is currently conducting an ongoing safety review of oral osteoporosis drugs (bisphosphonates) of a possible link to esophageal cancer, a serious form of cancer that could be a side effect of oral bisphosphonate use.

The defective drug lawyers at Parker Waichman LLP are investigating potential lawsuits on behalf of esophageal cancer victims and other oral bisphosphonate side effects. If you or someone you care about developed esophageal cancer that might be associated with one of these drugs, you may be able to obtain compensation for your medical bills, lost wages, and pain and suffering by filing a bisphosphonate esophageal cancer lawsuit. To learn how our personal injury lawyers can help you, please contact us today.

Oral Bisphosphonates and Esophogeal Cancer Risk

Oral bisphosphonates include the drugs Fosamax, Actonel, Boniva, Atelvia, Didronel, and Skelid. Oral bisphosphonates are used for the prevention and treatment of osteoporosis, a disease that makes bones weak and prone to break, as well as other bone diseases such as Paget's disease. One side effect of oral bisphosphonates is irritation of the esophagus, which can lead to esophagitis or esophageal ulcers, which may bleed.

The FDA is currently reviewing data from published studies to evaluate whether use of oral bisphosphonates is associated with an increased risk of esophageal cancer. According to a Drug Safety Communication issued by the agency on July 21, 2011, studies linking oral bisphosphonates to the development of esophageal cancer have been inconclusive so far. One of the largest studies reviewed by the FDA, a British study published in 2010, found that people taking oral bisphosphonates for more than five years may be doubling their risk of developing esophageal cancer. However, a second large study that drew data from the same British database found no increased risk.

In its communication, the FDA said it is unable to draw conclusions regarding the association between oral bisphosphonates and esophageal cancer, and for now, the agency continues to believe their benefits outweigh their risks.

Legal Help for Victims of Esophogeal Cancer from Oral Bisphosphonates

If you or a loved one was diagnosed with esophageal cancer that could be related to the use of oral bisphosphonates, you may have valuable legal rights. To learn more about filing a bisphosphonate esophageal cancer lawsuit, please fill out our online form or call 1 800 LAW INFO (1-800-529-4636) today.

Bisphosphonates-Esophageal CancerRSS Feed

Conflicting Bisphosphonate Studies Raise Esophageal Cancer Worries

May 3, 2012 | Parker Waichman LLP
In 2010, two studies on oral bisphosphonates reached differing conclusions regarding the drugs’ association with an increased risk of esophageal cancer.  One study, published in the Journal of the American Medical (JAMA) Association, found no increased risk for esophageal cancer among patients who used oral bisphosphonates like Fosamax.  Three weeks later, the second study, which found a doubling of the risk, appeared in the British Medical Journal.Strangely enough, both...

Long-Term Bisphosphonate Side Effects May Include Esophageal Cancer

Apr 3, 2012 | Parker Waichman LLP
Evidence continues to mount that long-term use of oral bisphosphonates, including Fosamax, could lead to serious consequences continues to mount.  One of those possible consequences could be the development of esophageal cancer.According to the U.S. Food & Drug Administration (FDA), approximately 5 million Americans use oral bisphosphonates like Fosamax. They are mostly used for the treatment and prevention of osteoporosis in post-menopausal women. Other approved indications include...

Health Canada Revises Bisphosphonate Labels with Fracture Warning

Dec 20, 2011 | Parker Waichman LLP
Health Canada has announced that its review of bisphosphonates has shown a slightly increased risk of atypical thigh fractures among people who use these medications.  Bisphosphonates, a class of drugs used to treat osteoporosis, are sold in Canada under the brand names Fosamax, Fosavance, Didrocal, Actonel and Aclasta.   In the U.S., brand names bisphosphonates include Actonel, Aredia, Bonefos, Boniva, Fosamax, Didronel, Reclast, Skelid and Zometa.Canadian labels for or brand...

Bisphoshonate Benefits Plateau at Five Years, FDA Says

Sep 8, 2011 | Parker Waichman LLP
Women who take oral bisphosphonates such as Fosamax to prevent broken bones from osteoporosis may not have to take them beyond five years to get their full benefit, a new U.S. Food & Drug Administration (FDA) staff report says.  This is good news, considering some of the serious side effects that have recently been linked with long-term use of bisphosphonates, including a rare type of thigh fractures.The FDA staff report was released ahead of an advisory panel meeting that will take a...

FDA: No Conclusion on Oral Bisphosphonate-Esophageal Cancer Link

Jul 21, 2011 | Parker Waichman LLP
The U.S. Food & Drug Administration (FDA) is reviewing a possible association between oral bisphosphonates and the development of esophageal cancer.  So far, findings from studies looking at the possible bisphosphonate-esophageal cancer link are conflicting, and the FDA has not reached any conclusions.  Oral bisphosphonates, used to treat osteoporosis and other bone diseases, include the drugs Fosamax, Actonel, Boniva, Atelvia, Didronel, and Skelid.  These medications can...

More Bisphosphonates-Esophageal Cancer News